Mutations in Danish patients with long QT syndrome and the identification of a large founder family with p.F29L in KCNH2

Michael Christiansen1†, Paula L Hedley1,2†, Juliane Theilade3†, Birgitte Stoeving1, Trond P Leren4, Ole Eschen5, Karina M Sørensen1, Anne Tybjærg-Hansen6, Lilian B Ousager7, Lisbeth N Pedersen8, Ruth Frikke-Schmidt6, Frederik H Aït1, Michael G Hansen9, Jim Hansen10, Poul E Bloch Thomsen10, Egon Toft11, Finn L Henriksen12, Henning Bundgaard3, Henrik K Jensen13 and Jørgen K Kanters9,14,15

Abstract

Background: Long QT syndrome (LQTS) is a cardiac ion channelopathy which presents clinically with palpitations, syncope or sudden death. More than 700 LQTS-causing mutations have been identified in 13 genes, all of which encode proteins involved in the execution of the cardiac action potential. The most frequently affected genes, covering > 90% of cases, are KCNQ1, KCNH2 and SCN5A.

Methods: We describe 64 different mutations in 70 unrelated Danish families using a routine five-gene screen, comprising KCNQ1, KCNH2 and SCN5A as well as KCNE1 and KCNE2.

Results: Twenty-two mutations were found in KCNQ1, 28 in KCNH2, 9 in SCN5A, 3 in KCNE1 and 2 in KCNE2. Twenty-six of these have only been described in the Danish population and 18 are novel. One double heterozygote (1.4% of families) was found. A founder mutation, p.F29L in KCNH2, was identified in 5 “unrelated” families. Disease association, in 31.2% of cases, was based on the type of mutation identified (nonsense, insertion/deletion, frameshift or splice-site). Functional data was available for 22.7% of the missense mutations. None of the mutations were found in 364 Danish alleles and only three, all functionally characterised, were recorded in the Exome Variation Server, albeit at a frequency of < 1:1000.

Conclusion: The genetic etiology of LQTS in Denmark is similar to that found in other populations. A large founder family with p.F29L in KCNH2 was identified. In 48.4% of the mutations disease causation was based on mutation type or functional analysis.

Background

Long QT syndrome (LQTS) is a genetic disease of the cardiac electrical system which presents clinically with palpitations, syncope and sudden death [1,2]. To date, more than 700 disease-causing mutations have been found in 13 genes [1-3] and the total number of mutations is probably larger [4]. All these genes are directly or indirectly involved in the execution of the cardiac action potential (AP) [2]. LQTS is a consequence of a prolongation of the repolarisation phase of the AP, caused by decreased activity of the repolarising inward K+-currents, \( I_{\text{Kr}} \) and \( I_{\text{Ks}} \) or increased late activity of the outward depolarising Na+-current, \( I_{\text{Na}} \). The delayed repolarisation leads to the appearance of early after depolarisations (EADs), due to enhancement of the Na⁺/Ca²⁺-exchanger and the L-type Ca²⁺ channel [5]. These, together with increased refractoriness, may trigger malignant arrhythmias [2].

In Denmark, genetic diagnostics of LQTS has been performed since 1996. From 2006 the management of LQTS patients has followed national guidelines [6]. The genetic diagnostic work is centred in five University cardiology clinics and patients are offered a five-gene screen of the most frequently affected genes, KCNQ1, KCNH2,
SCN5A, KCNE1 and KCNE2. Initially, the screen was performed using single strand conformation polymorphism analysis (SSCP) of the coding regions of the genes with intronic amplification primers [7-9]. In recent years, the mutation analysis has been performed by bi-directional Sanger sequencing of coding regions and all previous patients have been reanalysed. Here we report the disease-causing mutations identified in Danish LQTS families during the preceding 15 years. Furthermore, as the evidence base for considering mutations disease-causing is not always clear [10], and rare variants which are not associated with disease are found in controls [11], we report our reasoning for considering the variants found in this cohort disease-causing. Finally, we compare the distribution of mutations with that found in other population studies.

Methods

Patients

The patients were 70 Danish LQTS probands from unrelated families where mutation screening in the five LQTS associated genes KCNQ1, KCNH2, KCNE1, KCNE2 and SCN5A had led to the identification of a disease-causing mutation. LQT diagnosis was based on the clinical examination of patients, which was performed according to guidelines issued by the Danish Cardiology Society [6] by specialists in cardiology from Danish cardiology departments at Rigshospitalet, Sæby Hospitalet, Aalborg Hospital, Gentofte Hospital, Haderslev Hospital and Odense Hospital. All patients had a QTc interval > 440 ms for men and 450 ms for women. All patients were Caucasian. A clinical description of patients identified through a Danish nationwide survey comprising 59 families (all contributing to the current survey) has recently been published [12].

Mutation identification

Genomic DNA was extracted from EDTA-blood using the commercially available Maxwell™ 16 Blood DNA purification kit on the Maxwell® 16 System (Promega Biotech AB, Nacka, Sweden). Genetic screening was performed by bi-directional sequencing of PCR amplified exons with associated flanking intronic regions. Primers sequences are available on request. A minor proportion of mutations were identified at genetic departments at Skejby University Hospital, Rigshospitalet as well as in Norway and the Netherlands using other, but similar, technologies. All probands had the coding regions of the five genes sequenced. All mutations were verified by sequencing a second amplified amplicon. A large proportion of patients were examined for large deletions in KCNQ1, KCNH2, KCNE1, KCNE2 and a small part of SCN5A by multiplex-ligation-dependent amplification (MLPA) using the SALSA MLPA P114 kit (MRC-Holland, Amsterdam, The Netherlands).

Mutation and protein nomenclature

Mutation nomenclature uses numbering with the A of the initiation codon ATG as +1 (http://www.hgvs.org/mutnomen), based on the following RefSeqs: NM_000218.2 (KCNQ1), NM_000238.2 (KCNH2), NM_000335.4 (SCN5A), NM_000219.3 (KCNQ1) and NM_172201.1 (KCN2). All mutations were checked using Mutalyzer. The protein nomenclature was that used in the recent mutation update on LQTS [2].

Evaluation of sequence changes

Deletions, frameshift-, splice- and nonsense mutations were considered disease-causing if not found in controls. Concerning missense mutations, familial segregation was ascertained if possible, but nuclear family size was in all cases so small that it precluded a proper linkage analysis [12]. Instead it was ascertained that the family did not contain affected members that did not carry the family mutation. Conservation of residues across several species was examined. All genetic variants were evaluated in 182 randomly and anonymously collected blood donor controls (364 alleles). The frequency of identified variants was assessed using the Exome Variant Server (EVS) v.0.0.21. (http://evs.gs.washington.edu). It was established whether genetic variants had previously been associated with LQTS and whether functional analysis had been performed. The potential functional effect of changes in amino acid composition was assessed in silico using the prediction servers Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/) [13], SIFT (http://sift.bii.a-star.edu.sg) [14], and MutationAssessor (http://www.sanger.ac.uk/Software/MutationAssessor) [15]

Haplotyping KCNH2

Haplotyping was performed using the microsatellites D7S1824, D7S1826 up-stream of KCNH2 and D7S636, D7S3070, D7S483 and D7S1803 downstream of KCNH2 (Figure 1). CentiMorgan distances were obtained from the Map-O-Mat database for microsatellites (http://compgen.rutgers.edu/Mapomat/). PCR amplicons were generated using fluorescently end-labelled primers (available at NCBI UniSTS) at 0.4 μM per primer, per reaction. A loading mix

Figure 1 Location of microsatellite markers used in haplotyping the p.F29L and p.K101E mutations in KCNH2.
of 0.5 μl amplicon, 9 μl HiDi formamide (Applied Biosystems, Foster City, CA, USA) and 0.5 μl 600LIZ size standard (Applied Biosystems) was prepared, and DNA products were electrophoresed on an ABI PRISM® 3100 Genetic Analyser. Data were analysed using ABI GeneMapper software v4.0 (Applied Biosystems).

Results

Mutation screening

The results of the mutation screening are summarized in Tables 1, 2, 3. In the 70 families we found 64 different mutations; 22 in KCNQ1, 28 in KCNH2, 9 in SCN5A, 3 in KCNE1 and 2 in KCNE2. All patients were heterozygous carriers of a single mutation, except one double heterozygous proband (1.4% of families), who carried p.R583G in KCNQ1 and p.A93T in KCNE1. Twenty-six of the mutations have only been described in Danish LQTS patients (Tables 1, 2, 3), 18 have not been reported previously. Two mutations in KCNH2, p.F29L and p.K101E were found in 5 and 2 unrelated families, respectively. The MLPA analysis, applied to 65 of the probands, resulted in the identification of a single three exon (7-9) deletion, IVS6_IVS10del, in KCNQ1. None of the mutations were found in 384 control alleles.

KCNQ1 mutations

The twenty-two mutations identified in KCNQ1 seemed evenly spread out over the gene (Table 1). Only three of the mutations (p.F157C, IVS6_IVS10del and p.R583G) had not previously been described in other populations. The IVS6_IVS10del results, theoretically, either in the excision of a considerable part of the protein rendering it non-functional or in haploinsufficiency due to mRNA surveillance mechanisms [62], and is thus considered pathogenic. The remaining missense mutations all affect highly conserved residues and many missense mutations have been described in the S2-S3 and C-terminal regions of the protein, respectively [2]. The p.R583G affects a codon, where another missense mutation, p.R583C, has been shown to have an electrophysiological phenotype similar to that expected for a LQTS-associated mutation [42]. Among the 18 mutations previously seen in other populations, there were two frameshift mutations, two deletions, one splice-site mutation and one nonsense mutation. All of

| Gene | cDNA | Protein | Mutation type | Genomic region | Protein region | Phenotype | References |
|------|------|---------|---------------|----------------|---------------|-----------|------------|
| KCNQ1 | NM_000218 | NP_000209 | Missense | Exon_01 | N-term | RWS | [4,16] |
| DK | c.217C > A | p.P73T | Missense | Exon_02 | S2 | RWS | [17] |
| | c.470T > G | p.F157C | Missense | Exon_03 | S2-S3 | RWS | [4,18] |
| | c.572-576del | p.L191fs | Frameshift | Exon_04 | S3-S4 | RWS | [4,19] |
| | c.592A > G | p.I198V | Missense | Exon_05 | S4-S5 | RWS | [4,20-26] |
| | c.674C > T | p.S225L | Missense | Exon_06 | S5 | RWS | [4,20,21,25-28] |
| | c.667C > T | p.A226V | Missense | Exon_07 | S6 | RWS | [4,22] |
| | c.760G > A* | p.V254M | Missense | Exon_08 | C-term | RWS | [4,19,20,22,29-31] |
| | c.817C > T* | p.L273F | Missense | Exon_09 | C-term | RWS | [32] |
| DK | c.905C > T | p.A302V | Missense | Exon_10 | C-term | RWS | [2,26] |
| | c.944A > G* | p.Y315C | Missense | Exon_11 | C-term | RWS | [4,22] |
| | c.1015-1017del | p.P400fs | Splice-site | Exon_12 | C-term | RWS | [4,22] |
| | c.1087C > A | p.H363N | Missense | Exon_13 | C-term | RWS | [2,26] |
| | c.1096C > T | p.R366W | Missense | Exon_14 | C-term | RWS | [4,22,26,31] |
| | c.1202insC | p.P400fs | Deletion | Exon_15 | C-term | RWS | [4,20,39] |
| | c.1585G > T* | p.Q530X | Nonsense | Exon_16 | C-term | RWS | [4,20,25,28,40,41] |
| | c.1747C > T* | p.R583C | Missense | Exon_17 | C-term | RWS | [25,42] |
| DK | c.1747C > G | p.R583G | Missense | Exon_18 | C-term | RWS | This study |
| | c.1748G > A | p.R583H | Missense | Exon_19 | C-term | RWS | [38] |

DK: Only seen in patients of Danish origin. *In vitro functional characterisation performed. RWS: Romano-Ward syndrome.
these must be expected to result in haploinsufficiency due to mRNA surveillance mechanisms. Of the remaining missense mutations, four had been electrophysiologically characterized in vitro, i.e. p.V254M [21], p.L273I [21,27,28], p.Y315C [43] and p.R583C [42]. Thus, only four out of 15 LQTS-associated missense mutations (27%) had established electrophysiological characteristics at the molecular level.

**KCNH2 mutations**

Twenty-eight mutations were identified in **KCNH2**. Fourteen of these were located in the N-terminus, and five of these were located in the Per-Arnt-Sim domain. Five were located in the C-terminus, only five mutations were located in the pore-region (Table 2). This is surprising, as the majority of previously identified LQTS-associated mutations in **KCNH2** have been located in the pore region [2]. Fifteen of the mutations have only been described in the Danish population. Eight of the Danish specific mutations were deletions, or frameshift mutations. The remaining eight Danish-specific mutations were missense mutations and all involved conserved amino acid residues. Among the mutations found in other populations, two were frameshift mutations, one was nonsense and 10 were missense mutations. Only one of these missense mutations, p.F29L, had been demonstrated to have an in vitro electrophysiological effect compatible with LQTS [43], so the remainder were considered disease-associated based on the evolutionary conservation of the involved amino acid residue and the absence of the mutation among 364 control alleles as well as a previously reported association with LQTS. The observation of the association of these

| Gene | cDNA | Protein | Mutation type | Genomic region | Protein region | Phenotype | References |
|------|------|---------|---------------|----------------|---------------|-----------|------------|
| **KCNH2** | NM_000238 | NP_000229 | | | | | |
| DK | c.65T > C | p.F22S | Missense | Exon_01 | N-term | RWS | This study |
| DK | c.87C > A | p.F29L | Missense | Exon_01 | N-term | RWS | [4,26,43] |
| DK | c.88-90del | p.I30del | Deletion | Exon_01 | N-term | RWS | This study |
| DK | c.221C > T | p.T74M | Missense | Exon_02 | PAS | RWS | [4,38] |
| DK | c.234_241dupTGCCCGGC | p.A83fs | Frameshift | Exon_02 | PAS | RWS | This study |
| DK | c.287T > C | p.I96T | Missense | Exon_02 | PAS | RWS | [8] |
| DK | c.301A > G | p.K101E | Missense | Exon_02 | PAS | RWS | [8,44] |
| DK | c.326T > C | p.L109P | Missense | Exon_03 | N-term | RWS | This study |
| DK | c.446insC | p.R148fs | Frameshift | Exon_03 | N-term | RWS | This study |
| DK | c.453delC | p.P151fs | Frameshift | Exon_03 | N-term | RWS | [45] |
| DK | c.526C > T | p.I109P | Missense | Exon_04 | N-term | RWS | [45] |
| DK | c.555-560del | p.G184-G188del | Deletion | Exon_04 | N-term | RWS | This study |
| DK | c.1096C > T | p.R366X | Nonsense | Exon_05 | N-term | RWS | [4,8] |
| DK | c.1199T > A | p.H400N | Missense | Exon_06 | N-term | RWS | [8] |
| DK | c.1283C > T | p.S428L | Missense | Exon_06 | S1-S2 | RWS | [38] |
| DK | c.1286delC | p.S428fs | Frameshift | Exon_06 | S1-S2 | RWS | [46] |
| DK | c.1591-1671del | p.R531-L539del | Deletion | Exon_07 | S4-S5 | RWS | This study |
| DK | c.1682C > T | p.A561V | Missense | Exon_07 | SS | RWS | [4,19,25,47] |
| DK | c.1714G > C | p.G572R | Missense | Exon_07 | SS-pore | RWS | [48] |
| DK | c.1750G > A | p.G584S | Missense | Exon_07 | Pore | RWS | [25,45] |
| DK | c.1862G > A | p.S621N | Missense | Exon_07 | Pore | RWS | [8,49,50] |
| DK | c.1886A > G | p.N629S | Missense | Exon_07 | Pore | RWS | [4,51] |
| DK | c.1898A > G | p.N633S | Missense | Exon_07 | Pore-S6 | RWS | [51] |
| DK | c.2111_2114dup | p.W705fs | Frameshift | Exon_08 | C-term | RWS | This study |
| DK | c.2573T > C | p.I858T | Missense | Exon_10 | C-term | RWS | This study |
| DK | c.2753C > T | p.A913V | Missense | Exon_12 | C-term | RWS | [4,16] |
| DK | c.2786delC | p.P923fs | Frameshift | Exon_12 | C-term | RWS | [52] |
| DK | c.3000-3102del | p.S1029fs | Frameshift | Exon_13 | C-term | RWS | This study |

DK: Only seen in patients of Danish origin. *In vitro functional characterization performed. RWS: Romano-Ward syndrome.
mutations with LQTS in the Danish population corroborates their role in the causation of LQTS. Finally, a large number of mutations in the regions affected by the mutations described here, have been associated with LQTS [2].

All the remaining missense mutations in KCNH2, except p.A913V, were conserved to the level of zebrafish. The p.A913V mutation changed an alanine into a valine, where the valine was found at the same codon in rodents. However, the mutation had previously been associated with LQTS [16] and in the absence of deviations from familial disease segregation, and the absence of other mutations in the five genes as well as of the mutation in 364 control alleles, it was considered disease-causing.

SCN5A mutations

Nine mutations were identified in SCN5A (Table 3), five of which have only been described in the Danish population. Four mutations have not been reported before. Two mutations were intronic splice-site mutations and the remaining mutations were missense mutations located in the DI, DIV and C-terminal regions. This distribution is compatible with the one found when accumulating all known SCN5A LQTS-associated mutations [2]. The splice-site mutations were considered disease-causing because they are believed to result in aberrant mRNA splicing resulting in the synthesis of SCN5A ion channels with prolonged depolarisation contributing to delayed repolarisation. The splice mutations most likely do not result in haploinsufficiency as this would most likely give a Brugada syndrome phenotype [63]. One of the missense mutations, p.P2005A, has previously been associated with sudden infant death syndrome and shown to result in late persistent $I_{Na}$ current, compatible with LQTS [53]. An in vitro electrophysiological analysis of the functional consequence of the p.L1785Q mutation has shown that it results in increased late persistent $I_{Na}$ current, but also in a reduction of the total $I_{Na}$ (Kanters et al., submitted), suggesting that the electrophysiological phenotype may be a combination of Brugada syndrome and LQTS, as previously described for SCN5A mutations [63], e.g. the p.E1784K mutation [64]. The remaining missense mutations interfere with conserved residues and have not been found in controls; further the mutations p.F1596I and p.V1597M, are located in the C-terminal part of SCN5A, where mutations causing LQTS are particularly frequent [2]. The rare polymorphism p.D1819N, known to be associated with increased QT-interval in normal individuals [65], was found in a single p.F29L family and not considered pathogenic, despite being previously reported as associated with LQTS [57] The C-terminally located mutations are likely to interfere with fast inactivation of the $I_{Na}$ current [66]. Likewise, the remaining missense mutations, p.G319S, p.R340W and p.V411M, are located in the DI-S5-S6 region, a region with a high frequency of LQTS-associated mutations [2].

KCNE1 mutations

Three mutations were found in KCNE1, two of which, p.G60D and p.A93T, have only been found in the Danish population and have not been reported before. The p.

---

Table 3 Mutations identified in SCN5A, KCNE1 or KCNE2

| Gene       | cDNA       | Protein        | Mutation type | Genomic region | Protein region | Phenotype | References |
|------------|------------|----------------|---------------|----------------|----------------|-----------|------------|
| SCN5A      | NM_000335  | NP_000326      | Intron, splice| IVSS           | D1-S3          | RWS       | This study |
| DK         | c.611+1G > A| p.G319S       | Missense      | Exon_08        | D1-S5-S6       | RWS       | [7]        |
| DK         | c.1018C > T | p.R340W       | Missense      | Exon_09        | D1-S5-S6       | RWS       | [4]        |
| DK         | c.1441-3C > A| p.V411M       | Missense      | Exon_10        | D1-S6          | RWS       | [4,16]     |
| DK         | c.4783T > A | p.F1595I      | Missense      | Exon_27        | DIV-S3         | RWS       | [4]        |
| DK         | c.4786G > A | p.V1596M      | Missense      | Exon_27        | DIV-S3         | RWS       | This study |
| DK         | c.5354T > A*| p.L1785Q      | Missense      | Exon_28        | C-term         | RWS       | This study |
| DK         | c.6013G > G*| p.P2005A      | Missense      | Exon_28        | C-term         | RWS       | [53]       |
| KCNE1      | NM_000219  | NP_000210     | Missense      | Exon_03        | TM             | RWS       | This study |
| DK         | c.179G > A | p.G60D        | Missense      | Exon_03        | Cyto           | RWS       | [4,25,52-56] |
| DK         | c.226G > A*| p.D76N        | Missense      | Exon_03        | Cyto           | RWS       | This study |
| KCNE2      | NM_172201  | NP_751951     | Missense      | Exon_02        | TM             | RWS       | [4,57-61] |
| DK         | c.197G > A*| p.V65M        | Missense      | Exon_02        | TM             | RWS       | [59]        |

DK: Only seen in patients of Danish origin. *In vitro functional characterization performed. RWS: Romano-Ward syndrome.
A93T was found associated with p.R583G in KCNQ1 in an isolated proband, where family data were not attainable. The p.G60D and p.D76N interfered with amino acid residues conserved in human, rat, mouse, cow and frog, whereas the alanine at residue 93 was only conserved in mouse, rat, cow and human. However, the N-terminus of frog minK is not conserved at all from amino acid residue 85 – 105 in the human sequence (corresponding to residue 80 – 95 in the frog minK sequence). However, the missense mutations p. Y81C, p.W87R, p.R98W, and p.P127T – as well as p.D76N, located in the cytoplasmic C-terminus of minK, have previously been associated with LQTS [2].

**KCNE2 mutations**

Two mutations were found, p.I57T and p.V65M, both previously described in other populations as associated with LQTS [57,58] and shown to interfere with Kv7.1 function [59] in a way compatible with an association with LQTS. Both interfered with highly conserved residues and were not found in 384 control alleles.

**Disease causation**

The association between a mutation and disease is of paramount importance when the mutation findings are used for cascade screening and clinical management as is the case in Denmark [12]. This is a particular problem when family data are not sufficient to establish linkage. As none of the mutations are present in the 364 control alleles and all but three (SCN5A:p.P2005A, KCNE1:p.D76N and KCNE2: p.I57T) were absent from the EVS, moreover, the three variants reported here occurred at frequencies <1:1000, it is therefore unlikely that the variants reported here are polymorphisms. Frame-shift, splice-site- nonsense- or indel mutations represent 31.2% of the mutations identified in this cohort (Tables 1, 2, 3). Such mutations have a direct effect on the integrity of the polypeptide chain and are considered explanatory for LQTS. However, the remaining 68.8% are missense mutations, that need to be differentiated from the naturally occurring functionally insignificant non-synonymous variants in the same proteins. A classical method of supporting disease causality in LQTS is electrophysiological examination of mutated channel proteins to disclose a reduction in repolarising K⁺ current (KCNQ1, KCNH2, KCNE1, KCNE2) or late persistence of depolarising Na⁺ current (SCN5A) [2]. Such information, however, was only available for 22.7% of the missense mutations (Tables 1, 2, 3).

We used the prediction servers Polyphen-2, SIFT and Mutation Assessor to assess the significance of all the missense mutations for interference with protein function. The results are given in Table 4. As expected the majority of mutations where an electrophysiological assessment was available (p.V254M, p.L273F, p.Y315C, p.R583C in KCNQ1, p.F29L in KCNH2, p.L1785Q in SCN5A, p.D76N in KCNE1, p.I57T and p.V65M in KCNE2) were found to have an effect on protein function. One mutation, p.P2005A in SCN5A was not found to be disruptive of protein function, despite having been determined to cause functional impairment by in vitro electrophysiological assessment. This suggests that the sensitivity of these prediction servers is reasonable. The remaining, not functionally characterised, missense mutations, with the exception of KCNQ1 - p.P73T, p.R583G, p.R583H; KCNH2:p.A913V and KCNE1:p.A93T, were all found to be at least possibly disruptive of protein function.

**The founder mutations in KCNH2**

Two of the missense mutations, p.F29L [43] and p.K101E [44], were found in five and two “unrelated” families, respectively. Haplotype analysis, using six polymorphic microsatellite markers, spanning 24.6 cM, flanking the KCNH2 gene at distances ranging from 10.1 Mb 3’ to 2.9 Mb 5’ as shown in Figure 1, demonstrated that both mutations were founder mutations (Additional file 1: Table S1).

**Population distribution of mutations**

The distribution of Danish LQTS mutations is compared with four other large mutation surveys comprising verified LQTS patients in Table 5. The proportion of KCNQ1 mutations seems to be lower in Danish patients, 34.3%, than in other populations, where the proportion of KCNQ1 mutations ranged from 39.4% - 48.6%. This trend was not significant, however, using a Chi-Square test. The proportion of KCNH2 mutations in Denmark is within the range seen in the other populations, whereas the proportion of patients with mutations in the three rarely affected genes, SCN5A, KCNE1 and KCNE2 is considerably higher, 23.7%, than seen in the other populations (range: 10.7% - 16.2%). The distribution of mutation types does not seem to differ substantially between the populations. Likewise, the frequency of compound heterozygosity was similar in the populations where it was established. In a Norwegian study no compound heterozygotes were convincingly demonstrated, but 18 cases of Jervell and Lange-Nielsen syndrome had been found [67].

**Discussion**

We have identified 64 different mutations in 70 Danish LQTS families referred for five-gene screening. This is by far the highest number of different mutations identified per capita in any country and it amounts to approximately 1: 72.000 inhabitants. The signature of the genetics of LQTS in Denmark is that of many “private” mutations (Tables 1, 2, 3). With respect to this considerable inter- and inter-genic variation, the Danish mutation spectrum is similar to that found in other populations
However, there was a trend, albeit not significant, that the proportion of mutations in \textit{KCNQ1} is reduced and the proportion of mutations in \textit{SCN5A}, \textit{KCNE1} and \textit{KCNE2} correspondingly increased in the Danish LQTS patients. The same tendency is registered when comparing the Danish mutation spectrum to a collection of mutations identified in the five genes in persons referred for LQT testing, but where no knowledge on the clinical phenotype was available [4]. The relatively high frequency of mutations in the more rarely affected genes stresses the need of performing a five-gene screen when establishing the etiology of individual Danish LQTS families.

The patients described here were studied and collected over a long span of years, from 1996 – 2010. In this period the clinical picture of LQTS was better defined, the possibility of referral for genetic analysis increased and the indication for genetic analysis in LQTS cases was established in 2006 [6]. Furthermore, detailed clinical information was variable in quality, therefore it can not be excluded that, in some cases, other factors, e.g. structural heart disease or mixed phenotypes, might not have been identified and taken into account. Consequently, it is very difficult to establish a success rate for the genetic screening across this period. But it is probably comparable to the 70% reported from Norway in a much smaller collection of mutations [67]. Likewise, we cannot really state anything about the cost-effectiveness of including more genes in the basic screen or the suitability or cost-effectiveness of MLPA analysis of the five genes. A large proportion of cases, 65/70 had MLPA analysis performed in order to detect larger insertion/deletion mutations and a single case with a three exon deletion in \textit{KCNQ1} was identified. However, considering the relatively low cost of MLPA analysis and the possibility to detect deletions that would have escaped classical Sanger sequencing, our data suggests that MLPA analysis – or more extensive methods for detection of minor structural abnormalities - should be part of the five gene screen as the frequency of deletions (1.4%) is comparable to that of \textit{KCNE} mutations.

In general, disease causation was based on the identification of a mutation that; either resulted in a deletion or a frameshift, introduced a stop codon or disrupted correct splicing. In the case of missense mutations, the mutation should involve the exchange of a conserved amino acid.
acid and not be present in > 100 control alleles. If the mutation had previously been associated with LQTS this strengthened the argument for disease-causation. Functional assessment was not available for novel mutations. However, a large proportion, 48.4%, of mutations were classified as disease-causing as a consequence of the mutation type or the results of functional \textit{in vitro} assessment.

None of the mutations were present in Danish controls and three were found at very low frequencies in the EVS. The remaining missense mutations all, with five exceptions, were positive for disrupting protein function in one or several prediction servers. The prediction servers had a reasonable sensitivity, 9/10 functionally characterised mutations were correctly classified, but detailed analyses on larger datasets are necessary to establish specificity. Despite the promising performance of protein function interference prediction servers it will still be of great significance to be able to perform a functional analysis of identified novel variants.

Interestingly, this study and a subsequent survey of the cardiology clinics revealed that Andersen syndrome, despite being originally described in Denmark [68], as well as Jervell and Lange-Nielsen syndrome and Timothy syndrome patients, are not found in Danish cardiology clinics (Kanters, pers.com.).

The identification of a large \textit{KCNH2} p.F29L founder family, comprising 7.1% of Danish LQTS families, is interesting, and the location of the family in the Northern part of Jutland, where it constitutes ca. 50% of affected families makes it easier to genotype patients from this part of Denmark. The p.F29L mutation has previously been found in North America [43] in a family of Northern European origin (Splawski, pers. com.). The mutation has been found to have an electrophysiological effect \textit{in vitro} compatible with LQTS [43].

Each LQTS family has to be carefully examined as there is a risk of compound heterozygosity or digenic inheritance. Our data suggest that this risk is similar to that reported in other countries (Table 5). The clarification of the individual significance of either mutation in a family with a compound heterozygous index patient requires cascade screening to be performed and identification of carriers of the single mutations. In our experience this is rarely possible due to the small size of families [12].

The translation of molecular findings in LQTS patients into patient-specific clinical management decisions is difficult due to the low level of strict evidence, the complexity of the genetics, including the existence of genetic modifiers of phenotype [10]. Some of these problems may be alleviated if the use of patient-specific pluripotent stem cells turns out to give relevant information [69]. However, until such new approaches become routine, it is, with reference to the large role played by the use of previously reported information on disease-causation, important that all mutation findings and clinical as well as molecular follow-up of mutations are made available to the larger scientific community.

Conclusions

The Danish spectrum of LQTS causing mutations is very similar to that of the rest of the world, even though the frequency of \textit{KCNQ1} mutations seems relatively reduced and the proportion of mutations in rarely affected genes increased. There was a considerable proportion of novel mutations identified, but they were distributed on the genes largely as seen elsewhere. Despite a shortage of functional information and a long collection period nearly all mutations identified were reasonably classified as causative. The identification of a large founder family with p.F29L in \textit{KCNH2} may become of importance for local

| Table 5 Distribution of mutations and mutation types in this study and four other large studies |
|-----------------------------------------------|
| This study | Berge et al [67] | Napolitano et al [38] | Tester et al [16] | Splawski et al [25] |
| Number of mutations | 64 | 37 | 233 | 211 | 177 |
| \textit{KCNQ1} (%) | 34.3 | 42.6 | 48.6 | 41.7 | 39.4 |
| \textit{KCNH2} (%) | 43.8 | 46.3 | 38.8 | 42.2 | 51.5 |
| \textit{SCN5A} (%) | 14.1 | 9.3 | 10.1 | 15.2 | 6.1 |
| \textit{KCNE1} (%) | 4.7 | 1.9 | 1.7 | 0.5 | 2.3 |
| \textit{KCNE2} (%) | 3.1 | 0.0 | 0.7 | 0.5 | 2.3 |
| Mutation type |
| Missense (%) | 68.8 | 64.9 | 72.0 | 75.0 | 72.3 |
| Nonsense (%) | 3.1 | 13.5 | 5.1 | 5.7 | 6.2 |
| Deletion (%) | 9.4 | 2.7 | 14.1 | 2.5 | 5.0 |
| Frameshift (%) | 14.1 | 13.5 | 6.1 | 11.4 | 9.6 |
| Splice site (%) | 4.7 | 5.4 | 2.7 | 4.3 | 6.7 |
| Compound heterozygotes (%)* | 1.4 | 0 | 3.9 | 5.4 | n.a. |

*Percentage of families.
patient management as well as studies into the prevention of sudden cardiac death in LQT2. Sharing of genotype and phenotype data as well as development of improved in silico predictions of functional consequences of mutations will improve the management of LQTS.

Additional file

Additional file 1: Table S1. Haplotyping of the p.K101E and p.F29L families.

Competing interest

The authors declare that they have no competing interests.

Authors’ contributions

MC: participated in the design of the study, data acquisition, interpretation and drafting the manuscript; PLH: participated in data acquisition and data interpretation as well as critical revision of the manuscript; BS: participated in data acquisition, analysis and interpretation; JT: participated in data acquisition, analysis and interpretation as well as critical revision of the manuscript; TFL: participated in data acquisition, analysis and interpretation; OE: participated in data acquisition, analysis and interpretation; KMS: participated in data acquisition and analysis; ATh: participated in data acquisition, analysis and interpretation; LBO: participated in data acquisition, analysis and interpretation; LNP: participated in data acquisition, analysis and interpretation; MGR: participated in data acquisition, analysis and interpretation; JH: participated in data acquisition, analysis and interpretation; RF: participated in data acquisition, analysis and interpretation; FHA: participated in data acquisition and analysis; MG: participated in data acquisition, analysis and interpretation; HK: participated in data acquisition, analysis and interpretation; EF: participated in data acquisition, analysis and interpretation; ET: participated in data acquisition, analysis and interpretation; FLH: participated in data acquisition, analysis and interpretation; JH: participated in data acquisition, analysis and interpretation; JI: participated in the design of the study, data acquisition and interpretation as well as critical revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Dr. Igor Splawski, Novartis Institutes for Biomedical Research and Professor Mike Sanguinetti, University of Utah, are thanked for help with information on the KIR3.4 mutation. The Danish Strategic Research Council is thanked for financial support.

Author details

1Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Ørestad Boulevard 5, 2300, Copenhagen, Denmark. 2US/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Department of Biomedical Science, University of Stellenbosch, Cape Town, South Africa. 3The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 4Department of Medical Genetics, University Hospital Rikshospitalet, Oslo, Norway. 5Department of Cardiology, Ålborg Hospital, Aalborg University, Ålborg, Denmark. 6Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 7Department of Clinical Genetics, Odense University Hospital, Odense, Denmark. 8Department of Molecular Medicine, Aarhus University Hospital Skejby, Aarhus, Denmark. 9Department of Internal Medicine, Haderslev Hospital, Haderslev, Denmark. 10Department of Cardiology, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. 11Center for Sensory-Motor Interaction, Aalborg University, Ålborg, Denmark. 12Department of Cardiology, Odense University Hospital, Odense, Denmark. 13Department of Cardiology, Aarhus University Hospital Skejby, Aarhus, Denmark. 14Institute of Biomedical Science, University of Copenhagen, Copenhagen, Denmark. 15Danish Arrhythmia Research Center (DARC), Copenhagen, Denmark.

Received: 4 October 2013 Accepted: 18 February 2014

Published: 7 March 2014

References

1. Crotti L, Gelano G, Dagradi F, Schwartz PJ: Congenital long QT syndrome. Orphanet J Rare Dis 2008, 3:18.
2. Hedley PL, Jorgensen P, Schlamowitz S, Wangari R, Moodman-Smook J, Brink PA, Kantes JK, Corfeld VA, Christiansen M: The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat 2009, 30(11):1486–1511.
3. Yang Y, Liang B, Liu J, Li J, Grunnet M, Olsen SP, Rasmussen HB, Ellinor PT, Gao L, Lin X, Li L, Wang L, Xiao J, Liu Y, Liu Y, Zhang S, Liang D, Peng L, Jespersen T, Chen YH: Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet 2010, 86(6):872–880.
4. Kapplinger JD, Testor DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD, Wilde AA, Ackerman MJ: Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm 2009, 6:992–1307.
5. Antzelevitch C: Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. Am J Physiol Heart Circ Physiol 2007, 293(4):H2024–2038.
6. DCS: Arveilge hjärtesyndrom. Volume 1. 1st edition. Copenhagen: KLS Grafisk Hus A/S; 2006.
7. Hofman-Bang L, Behr ER, Hedley P, Tfelt-Hansen J, Kantes JK, Haunsoe S, McKenna WJ, Christiansen M: High-efficiency multiplex capillary electrophoresis single-strand conformation polymorphism (multi-CE-SSCP) mutation screening of SCNSA: a rapid genetic approach to cardiac arrhythmia. Clin Genet 2005, 69(4):504–511.
8. Larsen LA, Andersen PS, Kantes J, Svendsen IH, Jacobsen JR, Vuust J, Wettrett G, Traneljaerg L, Rathi J, Christiansen M: Screening for mutations and polymorphisms in the genes KCNH2 and KCNE2 encoding the cardiac HERG/MIRP1 ion channel: implications for acquired and congenital long QT syndrome. Clin Chem 2001, 47(13):1390–1395.
9. Larsen LA, Andersen PS, Kantes J, Jacobsen JR, Vuust J, Christiansen M: A single strand conformation polymorphism/heteroduplex (SSCP/HHD) method for detection of mutations in 15 exons of the KVLQT1 gene, associated with long QT syndrome. Clin Chem Acta 1999, 280(1–2):113–125.
10. Moller DV, Pecini R, Gustafsson F, Hassager C, Hedley P, Jespersgaard C, Torp-Pedersen C, Christiansen M, Kober LV: Hereditary hemochromatosis (HFE) genotypes in heart failure: relation to etiology and prognosis. BMC Med Genet 2010, 11:17.
11. Kapa S, Testor DJ, Salisbury BA, Harris-Kerr C, Pungsovita MS, Alders M, Wilde AA, Ackerman MJ: Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. Circulation 2009, 120(18):1752–1760.
12. Thelade J, Kantes J, Henriksen FL, Silba-Hansen M, Svendsen JH, Eschen O, Toft E, Reimers J, Tyljaerg-Hansen A, Christiansen M, Jensen HK, Bundgaard H: Cascade screening in families with inherited cardiac diseases driven by cardiologists: feasibility and nationwide outcome in long QT syndrome. Cardiology 2013, 126(2):131–137.
13. Adzhubei I, Jordan DM, Sunyaev SR: Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet, Chapter 7(Unit 7):20.
14. Sim NL, Kumar P, Hu J, Henkoff S, Schneider G, Ng PC: SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 2012, 40(Web Server issue):W452–457.
15. Reva B, Antipin Y, Sander C: Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011, 39(17):e118.
16. Testor DJ, Will ML, Haglund CM, Ackerman MJ: Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2005, 2(6):507–517.
17. Larsen LA, Christiansen M, Vuust J, Andersen PS: High-throughput single-strand conformation polymorphism analysis by automated capillary electrophoresis: robust multiplex analysis and pattern-based identification of allelic variants. Hum Mutat 1999, 13(4):318–327.
18. Liu W, Yang J, Hu D, Kang C, Li C, Zhang S, Li P, Chen Z, Qin X, Ying K, Li Y, Li X, Zhou Z, Chen Y, Chen S, Wang Q, KCNQ1 and KCNE2 mutations associated with long QT syndrome in a Chinese population. Hum Mutat 2002, 20(6):475–476.
19. Priori SG, Napolitano C, Schwartz PJ: Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999, 99(4):529–533.
20. Moss AJ, Shimizu W, Wilde AA, Towbin JA, Zareba W, Robinson JL, Qi M, Vincent GM, Ackerman MJ, Kaufman ES, Hofman N, Seth R, Kamakura S,
Miyamoto Y, Goldenberg I, Andrews ML, McNitt S. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 2007, 115(19):2481–2489.

21. Wang Q, Curran ME, Splawski I, Burn TC, Milholand JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Toubon JA, Moss AJ, Atkinson DL, Landes GM, Connett TD. Keating MT. Positional cloning of a novel potassium channel gene: KVLQ1T1 mutations cause cardiac arrhythmias. Nat Genet 1996, 12(1):17–23.

22. Choi G, Kopplin LJ, Tester DJ, Will ML, Haglund CM, Ackerman MJ. Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmias. Circulation 2004, 110(5):2119–2124.

23. Denger C, Denjoy I, Berthet N, Neyroud SH, Shirnizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL Jr. Roden DM. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002, 105(6):1943–1948.

24. Christensen M, Tonder N, Larsen LA, Andersen PS, Simonsen H, Oyen N, Kanters JK, Jacobsen JR, Foisdal I, Wettgeil G, Kjeldsen K. Mutations in the HERG K + channel: a novel link between long-QT syndrome and sudden infant death syndrome. Am J Cardiol 2003, 93(5):433–444.

25. Shalaby FY, Levesque PC, Yang WP, Little WA, Conder ML, Jenkins-West T, Biaura MA. Dominant-negative KVLQ1T1 mutations underlie the LQT1 form of long QT syndrome. Circulation 1997, 96(6):1733–1736.

26. Wilson AJ, Quinn KV, Graves FM, Bittner-Glindzicz M, Tinker A. Abnormal KCNQ1 trafficking influences disease pathogenesis in hereditary long QT syndromes (LQT1). Cardiovasc Res 2005, 67(3):476–486.

27. Shalaby FY, Levesque PC, Yang WP, Little WA, Conder ML, Jenkins-West T, Biaura MA. Dominant-negative KVLQ1T1 mutations underlie the LQT1 form of long QT syndrome. Circulation 1997, 96(6):1733–1736.

28. Splawski I, Shen J, Timothy KW, Lehmann MH, Piori S, Robinson JL, Moss AJ, Schwartz PJ, Toubin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT syndrome genes. KVLQ1T1, HERG, KCNQ1, KCNE1, and KCNE2. Circulation 2000, 102(10):1178–1185.

29. Struijk JJ, Kanters JK, Andersen MP, Hardtall T, Graff C, Christiansen M, Toft E. Classification of the long-QT syndrome based on discriminant analysis of T-wave morphology. Med Biol Eng Comput 2006, 44(7):543–549.

30. Napolitano C, Schwartz PJ, Brown AM, Ronchetti E, Bianchi L, Pinnavaia A, Christiansen et al. BMC Medical Genetics 2014, 15:31

31. Splawski I, Shen J, Neyroud N, Crucaud C, Benaimeur M, Chivoret G, Schwartz K, Coumel P, Guicheney P. KVLQ1T1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997, 96(6):2778–2781.

32. Magnussen A, Matthijs G, Gewillig M, Verhasselt P, Cohen N, Aerssens J. Mutation analysis in congenital Long QT Syndrome—a case with missense mutations in KCNQ1 and SCN5A. Gen Test 2003, 7(1):57–61.

33. Splawski I, Shen J, Timothy KW, Lehmann MH, Piori S, Robinson JL, Moss AJ, Schwartz PJ, Toubin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT syndrome genes. KVLQ1T1, HERG, KCNQ1, KCNE1, and KCNE2. Circulation 2000, 102(10):1178–1185.

34. Struijk JJ, Kanters JK, Andersen MP, Hardtall T, Graff C, Christiansen M, Toft E. Classification of the long-QT syndrome based on discriminant analysis of T-wave morphology. Med Biol Eng Comput 2006, 44(7):543–549.

35. Shalaby FY, Levesque PC, Yang WP, Little WA, Conder ML, Jenkins-West T, Biaura MA. Dominant-negative KVLQ1T1 mutations underlie the LQT1 form of long QT syndrome. Circulation 1997, 96(6):1733–1736.

36. Wilson AJ, Quinn KV, Graves FM, Bittner-Glindzicz M, Tinker A. Abnormal KCNQ1 trafficking influences disease pathogenesis in hereditary long QT syndromes (LQT1). Cardiovasc Res 2005, 67(3):476–486.

37. Shalaby FY, Levesque PC, Yang WP, Little WA, Conder ML, Jenkins-West T, Biaura MA. Dominant-negative KVLQ1T1 mutations underlie the LQT1 form of long QT syndrome. Circulation 1997, 96(6):1733–1736.

38. Wilson AJ, Quinn KV, Graves FM, Bittner-Glindzicz M, Tinker A. Abnormal KCNQ1 trafficking influences disease pathogenesis in hereditary long QT syndromes (LQT1). Cardiovasc Res 2005, 67(3):476–486.

39. Sherman J, Tester DJ, Ackerman MJ. Targeted mutational analysis of ankyrin-B in 541 consecutive, unrelated patients referred for long QT syndrome genetic testing and 200 healthy subjects. Heart Rhythm 2005, 2(11):1218–1223.

40. Huang L, Bittner-Glindzicz M, Tranebjaerg L, Tinker A. A spectrum of functional effects for disease causing mutations in the Jervell and Lange-Nielsen syndrome. Cardiovasc Res 2003, 51(6):670–680.

41. Tyson J, Tranebjaerg L, McIntartag M, Larsen LA, Christiansen M, Whiteford ML, Baten J, Aaskolen B, Sorland SJ, Lund O, Pembrey ME, Malcolm S, Bittner-Glindzicz M. Mutational spectrum in the cardioauditory syndrome of Jervell and Lange-Nielsen. Hum Genet 2000, 107(5):499–503.

42. Yang P, Kankel H, Drotel B, Yang T, Wei J, Witsawanat PC, Hofhofer SH, Shirnizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL Jr. Roden DM. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002, 105(6):1943–1948.

43. Chen J, Zou A, Splawski I, Keating MT, Sanguinetti MC. Long QT syndrome-associated mutations in the Per-Amt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation. J Biol Chem 1999, 274(15):10113–10118.

44. Christiansen M, Tonder N, Larsen LA, Andersen PS, Simonsen H, Oyen N, Kanters JK, Jacobsen JR, Foidtal I, Wettgeil G, Kjeldsen K. Mutations in the HERG K + ion channel: a novel link between long-QT syndrome and sudden infant death syndrome. Am J Cardiol 2003, 93(5):433–444.

45. Shalaby FY, Levesque PC, Yang WP, Little WA, Conder ML, Jenkins-West T, Biaura MA. Dominant-negative KVLQ1T1 mutations underlie the LQT1 form of long QT syndrome. Circulation 1997, 96(6):1733–1736.

46. Wilson AJ, Quinn KV, Graves FM, Bittner-Glindzicz M, Tinker A. Abnormal KCNQ1 trafficking influences disease pathogenesis in hereditary long QT syndromes (LQT1). Cardiovasc Res 2005, 67(3):476–486.

47. Shalaby FY, Levesque PC, Yang WP, Little WA, Conder ML, Jenkins-West T, Biaura MA. Dominant-negative KVLQ1T1 mutations underlie the LQT1 form of long QT syndrome. Circulation 1997, 96(6):1733–1736.

48. Wilson AJ, Quinn KV, Graves FM, Bittner-Glindzicz M, Tinker A. Abnormal KCNQ1 trafficking influences disease pathogenesis in hereditary long QT syndromes (LQT1). Cardiovasc Res 2005, 67(3):476–486.

49. Splawski I, Shen J, Timothy KW, Lehmann MH, Piori S, Robinson JL, Moss AJ, Schwartz PJ, Toubin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT syndrome genes. KVLQ1T1, HERG, KCNQ1, and KCNE1. Circulation 2000, 102(10):1178–1185.

50. Struijk JJ, Kanters JK, Andersen MP, Hardtall T, Graff C, Christiansen M, Toft E. Classification of the long-QT syndrome based on discriminant analysis of T-wave morphology. Med Biol Eng Comput 2006, 44(7):543–549.

51. Splawski I, Shen J, Timothy KW, Lehmann MH, Piori S, Robinson JL, Moss AJ, Schwartz PJ, Toubin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT syndrome genes. KVLQ1T1, HERG, KCNQ1, KCNE1, and KCNE2. Circulation 2000, 102(10):1178–1185.

52. Struijk JJ, Kanters JK, Andersen MP, Hardtall T, Graff C, Christiansen M, Toft E. Classification of the long-QT syndrome based on discriminant analysis of T-wave morphology. Med Biol Eng Comput 2006, 44(7):543–549.

53. Splawski I, Shen J, Timothy KW, Lehmann MH, Piori S, Robinson JL, Moss AJ, Schwartz PJ, Toubin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT syndrome genes. KVLQ1T1, HERG, KCNQ1, KCNE1, and KCNE2. Circulation 2000, 102(10):1178–1185.
56. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT: Mutations in the hminK gene cause long QT syndrome and suppress IKs function. *Nat Genet* 1997, 17(3):338–340.

57. Millat G, Chevalier P, Restier-Miron L, Da Costa A, Bouvagnet P, Kugener B, Fayol L, Gonzalez Armengod C, Oddou B, Charavat V, Froidefond E, Perraudin R, Rousson R, Rodriguez-Lafrasse C: Spectrum of pathogenic mutations and associated polymorphisms in a cohort of 44 unrelated patients with long QT syndrome. *Clin Genet* 2005, 70(3):214–227.

58. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA: MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. *Cell* 1999, 97(2):175–187.

59. Isbrandt D, Friederich P, Solth A, Haverkamp W, Ebneth A, Borggrefe M, Funke H, Sauter K, Breithardt G, Pongs O, Schulze-Bahr E: Identification and functional characterization of a novel KCNE2 (MiRP1) mutation that alters HERG channel kinetics. *J Mol Med* 2002, 80(8):S24–S32.

60. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smets HI, Schulze-Bahr E, Haverkamp W, Breithardt G, Cohen N, Aerssens J: Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. *J Mol Med* 2004, 82(3):182–188.

61. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL Jr, Goldstein SA: A common polymorphism associated with antibiotic-induced cardiac arrhythmia. *Proc Natl Acad Sci USA* 2000, 97(19):10613–10618.

62. Akimitsu N: Messenger RNA surveillance systems monitoring proper translation termination. *J Biochem* 2008, 143(1):1–8.

63. Hedley P, Jorgensen P, Schlamowitz S, Moolman-Smook J, Kanters J, Corfield V, Christiansen M: The genetic basis of Brugada syndrome: a mutation update. *Hum Mutat* 2009, 30(9):1256–1266.

64. Makita N, Behr E, Shimizu W, Horie M, Sunami A, Crotti L, Schulze-Bahr E, Fukushima S, Michio Suzuki N, Makiyama T, Itoh H, Christiansen M, McKeown P, Miyamoto K, Kamakura S, Schwartz PJ, George AL Jr, Roden DM: The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. *J Clin Invest* 2008, 118(6):2219–2229.

65. Gouas L, Nicaud V, Berthet M, Forhan A, Treillet L, Balkau B, Guicheney P: Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population. *Eur J Hum Genet* 2005, 13(11):1213–1222.

66. Wang DW, Yazawa K, George AL Jr, Bennett PB: Characterization of human cardiac Na+ channel mutations in the congenital long QT syndrome. *Proc Natl Acad Sci U S A* 1996, 93(23):13200–13205.

67. Berge KE, Haugaa KH, Fruh A, Anfinsen OG, Gjesdal K, Siem G, Oyen N, Greve G, Carlson A, Rosgnum TO, Hallenal M, Kongsgard E, Arnlie JP, Leren TP: Molecular genetic analysis of long QT syndrome in Norway indicating a high prevalence of heterozygous mutation carriers. *Scand J Clin Lab Invest* 2008, 68(3):362–368.

68. Andersen ED, Krasilnikoff PA, Overvad H: Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies: a new syndrome? *Acta Paediatr* 1971, 60(3):559–564.

69. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, Dorn T, Goedel A, Hohnke C, Hoffmann F, Seyfarth M, Sinnecker D, Schöning A, Laugwitz KL: Patient-specific induced pluripotent stem-cell models for long-QT syndrome. *N Engl J Med* 2010, 363(15):1397–1409.

doi:10.1186/1471-2350-15-31

Cite this article as: Christiansen et al.: Mutations in Danish patients with long QT syndrome and the identification of a large founder family with p.F29L in *KCNH2*. *BMC Medical Genetics* 2014 15:31.